Good morning and welcome to your Monday wake-up call. Yesterday was a collision of big drug approvals, surprise earnings beats and crypto shake-ups. If you blinked, you missed the catalysts driving momentum across every corner of the market. Here’s what you need to know before the opening bell.

1. EARNINGS BEAT SPARKS PEPSICO RALLY
PepsiCo sneak-punched expectations in its Q3 report, topping estimates on both the top line and the bottom line—even while dialing back its full-year profit outlook. Translation: they’re still squeezing more juice out of snack pricing power, and Wall Street loves it. If you’ve been hunting for a defensive play with an earnings beat pedigree, this one’s on your radar.

2. BIG BIO NEWS: FDA APPROVALS GALORE
– Teva just scored FDA approval for its once-monthly schizophrenia shot. It’s the rare example of pharma stepping up to make real patient-friendly dosing improvements—and the timing couldn’t be better as investors chase “news catalyst” plays in health care.
– Lupin slid through U.S. FDA clearance for its phytonadione injectable emulsion, staking its claim in the niche vitamin K market. Don’t sleep on these under-the-radar specialty drugs—they’re ripe for a potential short squeeze if hedge funds get caught flat-footed.

3. PHASE 3 DATA TRIGGERS BIOTECH RUNDOWN
Sebela Pharmaceuticals unveiled positive Phase 3 results for tegoprazan in non-erosive reflux disease at ACG 2026. Look for a potential deal or takeover chatter to heat up—big pharma loves gobbling up late-stage assets right before a new drug application hits the FDA.

4. CRYPTO: ETH LONGS & BITCOIN VOLATILITY
– Ethereum bulls are feeling frothy: ETH long positions just surged to four-year highs. Warning: positioning this stretched is asking for a nasty squeeze if even a minor catalyst hits.
– Meanwhile, Bitcoin’s overall volatility has cooled from its parabolic highs, yet we’re still seeing more extreme swings than back in 2018. If you’re playing crypto for alpha, buckle up—these chop-fest conditions reward nimble hands, not buy-and-holders.

5. SPOTLIGHT ON ATOSSA’S CVR AGREEMENT
Atossa Therapeutics inked a contingent value rights pact, giving shareholders a slice of any future priority review voucher windfall. It’s a classic biotech move: minimal dilution now, huge payoff later if the FDA hands over that golden ticket. Could be a stealth short squeeze as nomination deadlines draw near.

MARKET OUTLOOK
No fresh policy bombs out of D.C. to shake rates or tax policy today, so expect headlines—like more M&A whispers or Fed speakers—to dictate the tape. If you’re craving momentum, chase the earnings-beat biotechs and FDA approvals; if you want danger, watch crypto leverage. Either way, don’t get left holding the bag when the next catalyst drops.

That’s your Monday – now go own the day.
– Your No-BS Market Desk